Links on this page relate to polycythemia vera.
General MPN information is at the main MPN guidelines and articles page.
Polycythemia Vera (PV) specific information
- Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis, Annals of Hematology, 2024
- Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL, Blood, 2024
- Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management, American Journal of Hematology, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera, Review, Vascular Health and Risk Management, 2023
- JAK2V617F allele burden in polycythemia vera: burden of proof, Blood, 2023
- Diagnostics and risk stratification for patients with polycythemia vera, Expert Roundtable Review, 2023
- Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b, Leukemia, 2022
- Appropriate management of polycythaemia vera with cytoreductive drug therapy – European LeukemiaNet recommendations, 2021
- Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival Leukemia’, 2021
- A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline, 2019
- A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis – A British Society for Haematology Guideline, 2018
- Basis of Hematocrit Treatment Guideline for PV: Cardiovascular Events and the Intensity of Treatment in Polycythaemia Vera, ‘NEJM’, 2013